-
Private Biotech Funding Takes a Steep Dive in H1 2025
Jul 03 2025 -
4D Molecular Therapeutics Accelerates Phase 3 AAV Program for 4D-150 in Wet AMD
Jul 03 2025 -
Abeona Therapeutics Strengthens Financial Position with $155 Million Sale of PRV
Jul 02 2025 -
Breakthrough AAV Gene Therapy Restores Hearing in Children and Adults with Genetic Deafness
Jul 02 2025 -
New Gene Therapy Strategy Rejuvenates CAR T-Cell Effectiveness Against Glioblastoma
Jul 02 2025 -
Moderna’s mRNA Flu Vaccine Shows Strong Phase 3 Efficacy in Older Adults
Jun 30 2025 -
Neurogene Secures FDA Alignment for Pivotal AAV Gene Therapy Trial (NGN-401) in Rett Syndrome
Jun 30 2025 -
AbbVie’s Strategic Leap into In Vivo CAR-T with $2.1 Billion Capstan Acquisition to Transform Autoimmune Disease Treatment
Jun 30 2025 -
Arcturus Therapeutics Announces Positive Phase 2 Interim Results for mRNA Therapy in OTC Deficiency
Jun 30 2025